BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 22829075)

  • 1. Menin as a hub controlling mixed lineage leukemia.
    Thiel AT; Huang J; Lei M; Hua X
    Bioessays; 2012 Sep; 34(9):771-80. PubMed ID: 22829075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Menin critically links MLL proteins with LEDGF on cancer-associated target genes.
    Yokoyama A; Cleary ML
    Cancer Cell; 2008 Jul; 14(1):36-46. PubMed ID: 18598942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The trithorax protein partner menin acts in tandem with EZH2 to suppress C/EBPα and differentiation in MLL-AF9 leukemia.
    Thiel AT; Feng Z; Pant DK; Chodosh LA; Hua X
    Haematologica; 2013 Jun; 98(6):918-27. PubMed ID: 23349306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele.
    Thiel AT; Blessington P; Zou T; Feather D; Wu X; Yan J; Zhang H; Liu Z; Ernst P; Koretzky GA; Hua X
    Cancer Cell; 2010 Feb; 17(2):148-59. PubMed ID: 20159607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis.
    Jin S; Zhao H; Yi Y; Nakata Y; Kalota A; Gewirtz AM
    J Clin Invest; 2010 Feb; 120(2):593-606. PubMed ID: 20093773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular basis of the mixed lineage leukemia-menin interaction: implications for targeting mixed lineage leukemias.
    Grembecka J; Belcher AM; Hartley T; Cierpicki T
    J Biol Chem; 2010 Dec; 285(52):40690-8. PubMed ID: 20961854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The same site on the integrase-binding domain of lens epithelium-derived growth factor is a therapeutic target for MLL leukemia and HIV.
    Murai MJ; Pollock J; He S; Miao H; Purohit T; Yokom A; Hess JL; Muntean AG; Grembecka J; Cierpicki T
    Blood; 2014 Dec; 124(25):3730-7. PubMed ID: 25305204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis.
    Yokoyama A; Somervaille TC; Smith KS; Rozenblatt-Rosen O; Meyerson M; Cleary ML
    Cell; 2005 Oct; 123(2):207-18. PubMed ID: 16239140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct pathways affected by menin versus MLL1/MLL2 in MLL-rearranged acute myeloid leukemia.
    Chen Y; Jones KL; Anastassiadis K; Kranz A; Stewart AF; Grembecka J; Meyerson M; Ernst P
    Exp Hematol; 2019 Jan; 69():37-42. PubMed ID: 30315824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NUP98-MLL fusion in human acute myeloblastic leukemia.
    Kaltenbach S; Soler G; Barin C; Gervais C; Bernard OA; Penard-Lacronique V; Romana SP
    Blood; 2010 Sep; 116(13):2332-5. PubMed ID: 20558618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of MLL amino terminal sequences with menin is required for transformation.
    Caslini C; Yang Z; El-Osta M; Milne TA; Slany RK; Hess JL
    Cancer Res; 2007 Aug; 67(15):7275-83. PubMed ID: 17671196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanisms of MLL-associated leukemia.
    Yokoyama A
    Int J Hematol; 2015 Apr; 101(4):352-61. PubMed ID: 25773519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crystal structure of menin reveals binding site for mixed lineage leukemia (MLL) protein.
    Murai MJ; Chruszcz M; Reddy G; Grembecka J; Cierpicki T
    J Biol Chem; 2011 Sep; 286(36):31742-8. PubMed ID: 21757704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MLL-ENL-mediated leukemia initiation at the interface of lymphoid commitment.
    Ugale A; Säwén P; Dudenhöffer-Pfeifer M; Wahlestedt M; Norddahl GL; Bryder D
    Oncogene; 2017 Jun; 36(22):3207-3212. PubMed ID: 28068328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A MENage à Trois in leukemia.
    Roudaia L; Speck NA
    Cancer Cell; 2008 Jul; 14(1):3-5. PubMed ID: 18598937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis.
    Muntean AG; Tan J; Sitwala K; Huang Y; Bronstein J; Connelly JA; Basrur V; Elenitoba-Johnson KS; Hess JL
    Cancer Cell; 2010 Jun; 17(6):609-21. PubMed ID: 20541477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disordered epigenetic regulation in MLL-related leukemia.
    Zhang Y; Chen A; Yan XM; Huang G
    Int J Hematol; 2012 Oct; 96(4):428-37. PubMed ID: 23054645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent Progress of Small Molecule Menin-MLL Interaction Inhibitors as Therapeutic Agents for Acute Leukemia.
    Lei H; Zhang SQ; Fan S; Bai HR; Zhao HY; Mao S; Xin M
    J Med Chem; 2021 Nov; 64(21):15519-15533. PubMed ID: 34726905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Transcription Factor Addiction in Leukemia Imposed by the MLL Promoter Sequence.
    Lu B; Klingbeil O; Tarumoto Y; Somerville TDD; Huang YH; Wei Y; Wai DC; Low JKK; Milazzo JP; Wu XS; Cao Z; Yan X; Demerdash OE; Huang G; Mackay JP; Kinney JB; Shi J; Vakoc CR
    Cancer Cell; 2018 Dec; 34(6):970-981.e8. PubMed ID: 30503706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications.
    Milne TA; Martin ME; Brock HW; Slany RK; Hess JL
    Cancer Res; 2005 Dec; 65(24):11367-74. PubMed ID: 16357144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.